Approval · Notice of Compliance 2640 · 2001
TAZORAC: Notice of Compliance 2640
Issued May 30, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2640
- Date
- May 30, 2001
- Company
- Allergan IncMarkham, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New dosage form
- Therapeutic class
- Anti-psoriasis agent
Products in this notice
Medicinal ingredients
- TAZAROTENE 0.05 PER
- TAZAROTENE 0.1 PER